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Background: In diseased joints, the catabolic environment results in progressive joint dam-
age. Mesenchymal stem cells (MSCs) can have immunomodulatory effects by secreting
anti-inflammatory factors. To exert these effects, MSCs need to be triggered by pro-
inflammatory cytokines. To explore the potential of MSCs as a treatment for diseased
joints, we studied the effect of synovial fluid (SF) from donors with different joint diseases
and donors without joint pathology on the immunomodulatory capacities of human MSCs
in vitro. We hypothesized that SF of diseased joints influences the immunomodulatory
effects of MSCs. Materials and Methods: MSCs were cultured in medium with SF of
six osteoarthritis (OA) or six rheumatoid arthritis (RA) donors and three donors without
joint pathology were used as control. Gene expressions of IL-6, HGF, TNFa, TGFb1, and
indoleamine 2,3-dioxygenase (IDO) were analyzed. L-kynurenine concentration in condi-
tioned medium (CM) by MSCs with SF was determined as a measure of IDO activity by
MSCs. Furthermore, the effect of CM with SF on proliferation of activated lymphocytes
was analyzed. Results: Addition of SF significantly up-regulated the mRNA expression
of IL-6 and IDO in MSCs. SF(OA) induced significantly higher expression of IDO than
SF(control), although no difference in IDO activity of the MSCs could be shown with a
L-kynurenine assay. Medium conditioned by MSCs with SF(OA or RA) suppressed acti-
vated lymphocyte proliferation in vitro more than medium conditioned by MSCs without
SF or with SF(control). Discussion: SF can influence the expression of genes involved in
immunomodulation by MSCs and the effect on lymphocyte proliferation. We found indica-
tions for disease-specific differences between SFs but the variation between donors, even
within one disease group was high. These data warrant further research to examine the
potential application of MSC therapy in arthritic joints.
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INTRODUCTION
Osteoarthritis (OA) and rheumatoid arthritis (RA) are high
prevalent forms of arthritis. OA is mainly characterized by pro-
gressive functional loss and cartilage degeneration. Main factors
involved in cartilage degeneration are a variety of matrix degrad-
ing enzymes and pro-inflammatory cytokines (Goldring, 2000;
Goldring and Marcu, 2009). It is possible to treat the symp-
toms of OA with lifestyle changes, analgesics, non-steroidal anti-
inflammatory drugs (NSAIDs), or intra-articular injections with
corticosteroids or hyaluronic acid and the ultimate treatment for
end stage OA is joint replacement. A treatment to cure OA, how-
ever, is still not available. RA is an auto-immune disease initiated
by immune complexes that together with cytokines, complement,
and metalloproteinases (Weissmann, 2006) cause an inflamma-
tory and catabolic environment in the joint (Goldring and Marcu,
2009). It is a systemic disease characterized by persistent synovi-
tis, systemic inflammation, and auto-antibodies which eventually
cause joint damage with progressive cartilage degeneration and
bone alterations. There is a wide range of therapeutic options
for RA like analgesics, NSAIDs, disease-modifying anti rheumatic
drugs (DMARDs), and biologicals (Lee and Weinblatt, 2001; Scott
et al., 2010). However, to date there is no treatment available to
cure RA.
Human mesenchymal stem cells (MSCs), the progenitors of
connective tissue cells, are able to differentiate into different cell
types including chondrocytes (Caplan, 1991, 1994; Solchaga et al.,
2004; Caplan and Dennis, 2006). This has attracted the interest
of many people working in the area of cartilage repair. Besides
the ability to reconstruct tissues, MSCs also have the ability to
modulate the environment by secreting many immunomodulating
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and trophic factors like cytokines, chemokines, and growth fac-
tors (Deans and Moseley, 2000; Minguell et al., 2001; Kim et al.,
2005; Caplan and Dennis, 2006; Chen et al., 2006; Schinkothe
et al., 2008; Hoogduijn et al., 2010; Meisel et al., 2011). These fac-
tors have potent immunomodulatory capacity as demonstrated
in vitro by inhibition of T-lymphocyte proliferation after adding
MSCs in mixed lymphocyte reactions (Hoogduijn et al., 2010;
Landgraf et al., 2011). MSCs also inhibit the antibody produc-
tion of B lymphocytes and inhibit the generation and function of
antigen presenting cells (Sze et al., 2007; Chen et al., 2008; Hoog-
duijn et al., 2010). The stimulation of MSC by pro-inflammatory
cytokines like TNFa and IFNg strongly enhances the immunosup-
pressive function of MSCs (Klyushnenkova et al., 2005; Schinkothe
et al., 2008; Siegel et al., 2009; Eggenhofer et al., 2010; Hoogduijn
et al., 2010).
In a healthy joint environment, a balance exists between an ana-
bolic and catabolic state. In a situation of inflammation or chronic
damage, i.e., OA or RA, the environment becomes more catabolic
(Findlay and Haynes, 2005; Goldring and Marcu, 2009). All joint
tissues are exposed to synovial fluid (SF) and in OA and RA inflam-
matory factors are secreted into the SF. The aim of the present study
was to investigate whether SF of donors with OA, RA, or no joint
pathology triggers MSCs to become immunomodulatory. Since
inflammation plays a large role in RA and OA, we hypothesized
that MSCs will be triggered to become immunomodulatory. We
explored this by studying the effect of SF of OA and RA patients
as well as SF of non-pathological(control) donors on MSCs. Our
hypothesis was that MSCs conditioned in SF(RA) will express a
large anti-inflammatory effect compared to SF(control) due to the
high inflammation state of RA patients and MSCs conditioned
with SF(OA) will express a mild anti-inflammatory effect com-
pared to SF(control) as a reaction to a less inflamed environment
in joints of OA patients.
We evaluated the effect of SF on expression of genes of MSCs for
immunomodulatory factors. Furthermore, we performed a func-
tional assay to study the capacity of factors secreted by MSCs in
response of SF to inhibit proliferation of activated lymphocytes.
MATERIALS AND METHODS
SYNOVIAL FLUIDS
Fifteen SF samples were obtained from six OA patients, six RA
patients, and three donors without any joint pathology. SFs(OA)
were obtained from patients undergoing total knee replacement
surgery. All patients implicitly consented to the use of these fluids
for scientific research (with approval by Erasmus MC medical ethi-
cal committee protocol # MEC-2004-322). SFs(RA) were obtained
from RA patients with active inflammation of the knee during con-
sultation at the rheumatology outpatient clinic (with approval by
Erasmus MS medical ethical committee protocol # MEC-236.904-
2003-255). SFs(control) were purchased from SF donors without
joint diseases, post mortem within 24 h of death (Articular Engi-
neering, Northbrook, IL, USA). After aspiration, all SF samples
from the joints of all donors were centrifuged to remove debris.
Supernatant was stored at−80˚C.
To evaluate the inflammatory aspects of the different SFs we
did amplified enzyme linked immunosorbent assays (ELISA) to
quantify cytokines IL-6, TNFa (R&D Systems, Minneapolis, MN,
USA), and IFNg (Invitrogen, Carlsbad, CA, USA). Measurements
of IL-6, TNFa, and IFNg were performed in duplicate. All SFs were
treated with 1:3 hyaluronidase (1000 U/ml PBS, 10 min at 37˚C)
prior to ELISA measurements. ELISAs were carried out according
to the manufacturer’s instructions by means of a multilabel plate
reader (VersaMax™, Molecular Devices, Sunnyvale, CA, USA).
MSC ISOLATION
Mesenchymal stem cells were isolated from heparinized femoral-
shaft marrow aspirate of patients undergoing total hip arthroplasty
(with informed consent after approval by Erasmus MC med-
ical ethical committee protocol # MEC-2004-142). About 5–10 ml
marrow was harvested with a sterile Jamshidi needle into sterile
10 ml syringes containing 0.5 ml of heparin (1000 U/ml). About
30–100× 106 mononuclear cells were plated in a T175 flask in
25 ml expansion medium (Dulbecco’s Modified Eagle Medium
(DMEM) low glucose (Invitrogen, Carlsbad, CA, USA) containing
15% heat inactivated fetal calf serum (Lonza, Verviers, Belgium,
selected batch), 1.5µg/ml fungizone (All Invitrogen, Carlsbad,
CA, USA), 50µg/ml gentamicin (Invitrogen, Carlsbad, CA, USA),
1 ng/ml fibroblast growth factor-2 (Instruchemie B.V., Delfzijl, The
Netherlands), and 0.1 mM of l-ascorbic acid 2-phosphate (vit-
amin C; Sigma, St. Louis, MO, USA). After 24 h, non-adherent
cells and erythrocytes were removed by washing three times with
2% FCS in 1× PBS (Invitrogen, Carlsbad, CA, USA). Remaining
adherent cells were cultured in expansion medium at 37˚C and
5% carbon dioxide (CO2). Expansion media were renewed twice a
week. At subconfluent cells were trypsinized with a 0.25% trypsin
solution containing 0.01% EDTA (Invitrogen, Carlsbad, CA, USA)
and plated at a density of 2300 cells/cm2.
MSC CULTURE WITH SF
Cryopreserved MSCs of passage two were used for the experi-
ments. After thawing, MSCs were seeded in a T175 flask at a density
of 2300 cells/cm2, expanded for one passage and subsequently
plated in six well plates at a density of 4000 cells/cm2 for the exper-
imental conditions. At 70% confluence the existing medium was
discarded and the cells were washed three times using PBS (Invit-
rogen, Carlsbad, CA, USA). Subsequently 0.8 ml of DMEM low
glucose containing 9µg/ml fungizone and 50µg/ml gentamicin,
was applied per well. The different SFs(OA, RA, and control) were
added in triplicates to the media in a concentration of 20%. In
preliminary tests MSCs were cultured in 0, 10, or 25% SF of four
OA donors, Gene expression was not significantly different in 10
and 25% SF. Based on this and taking into account the availability
of the SF (from SF(control) we obtained maximal 1 ml per donor)
we decided to use 20% SF for all further experiments. All condi-
tions contained a total concentration of 1% ITS (BD Bioscience,
Bedford, MA, USA). Nine wells with only medium plus 1% ITS
were used as negative controls for unstimulated MSCs. After 48 h
of incubation, MSCs were harvested for gene expression analy-
ses and the conditioned medium (CM) was harvested and stored
at−80˚C.
GENE EXPRESSION ANALYSIS
After 48 h of incubation total RNA from MSCs was isolated
using RNeasy® microkit (Qiagen, Hilden, Germany) with RNeasy
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MinElute spin columns. After quantification of nucleic acids by
spectrophotometry (NanoDrop 2000, Thermo Scientific, Isogen
Life Science, IJsselstein, The Netherlands) the RNA was reverse
transcribed using a First Strand cDNA Synthesis kit (RevertAid™;
MBI Fermentas, St. Leon-Rot, Germany). Amplifications were per-
formed as 20µl reactions with real-time PCR. Thermocycler con-
ditions comprised an initial holding at 95˚C for 10 min, followed
by one step at 95˚C for 15 s and 60˚C for 60 s for 40 cycles. A disso-
ciation stage was added at the end using 95˚C for 15 s, 60˚C for 20 s,
and 95˚C for 15 s. For UBC, IL-6, HGF, TNF-α, qPCR™Mastermix
Plus for SYBR® Green I (Eurogentec, Nederland B.V., Maastricht,
The Netherlands) was used. For GAPDH, HPRT, IDO, and TGF-β1
TaqMan Master Mix (ABI, Branchburg, NJ, USA) was used. Sets of
primers and probes used in this study: GAPDH (NM_002046.3)
Fw: ATGGGGAAGGTGAAGGTCG Rv: TAAAAGCAGCCCTG-
GTGACC Probe: Fam-CGCCCAATACGACCAAATCCGTTGAC;
HPRT (NM_000194.2) Fw: TATGGACAGGACTGAACGTCTTG
Rv: CACACAGAGGGCTACAATGTG Probe: Fam-AGATGTGATG
AAGGAGATGGGAGGCCA; UBC (NM_021009.5) Fw: ATTTGG
GTCGCGGTTCTTG Rv: TGCCTTGACATTCTCGATGGT; IL-
6 (NM_000600.3) Fw: TCGAGCCCACCGGGAACGAA Rv:
GCAGGGAAGGCAGCAGGCAA; HGF (NM_000601.4) Fw:
GGCTGGGGCTACACTGGATTG Rv: CCACCATAATCCCCCT-
CACAT; TNF-aplha (NM_000594.2) Fw: GCCGCATCGC-
CGTCTCCTAC Rv: AGCGCTGAGTCGGTCACCCT; TGF-beta1
(NM_000660.4) Fw: GTGACAGCAGGGATAACACACTG Rv:
CATGAATGGTGGCCAGGTC Probe: Fam-ACATCAACGGGTTC
ACTACCGGC. IDO was detected using a taqman assay on demand
(Applied Biosystems, Capelle a/d IJssel, The Netherlands) of which
the primer sequence is not known to us. Data were collected and
quantitatively analyzed on an ABI Prism 7000 Sequence Detection
System (SDS) with SDS software, version 1.2.3 (Applied Biosys-
tems, Capelle a/d IJssel, The Netherlands). Gene expressions of
the cytokines and IDO in MSCs were calculated by cycle threshold
(CT) values. CT values of 36 and higher were considered as non-
expressed and set to 100 for further calculations. The CT values of
the housekeeper genes GAPDH, HPRT, and UBC were averaged
by using geometric averaging of every sample. This average is the
best keeper index (BKI) for every single sample. All separate CT
values were corrected to the BKI by using the 2−∆CT formula.
L-KYNURENIN ASSAY
In order to evaluate whether SF influenced IDO activity in
MSCs, we measured the concentration of l-kynurenine in the
CM and SFs. To correct for possible l-kynurenine in SF, the
SFs were diluted in the same concentration and the same
media as the CM and values were subtracted from the CM
values. Values of one of the OA donors could not be used
since no remaining SF was available for correction. Thirty
percent trichloroacetic acid was added to the samples in a
1:3 ratio and after 30 min incubation at 50˚C the samples
were centrifuged at 12000 rpm for 5 min. Supernatant of all
conditions were diluted 1:1 in Ehrlich reagent (200µg 4-
dimethylaminobenzaldehyde (Sigma, St. Louis, MO, USA) in
10 ml of glacial acetic acid) in duplicate in a 96-wells flat bottom
plate and absorbance was determined at 490 nm in a multil-
abel plate reader (VersaMax™, Molecular Devices, Sunnyvale, CA,
USA). l-kynurenine (Sigma, St. Louis, MO, USA) was used as
standard.
PBMC PROLIFERATION ASSAY
Peripheral blood mononuclear cells (PBMCs) were isolated from
buffy coats (Sanquin, Rotterdam, The Netherlands) of healthy vol-
unteers using Ficoll-Paque™Plus (GE Healthcare, Uppsala, Swe-
den) separation and stored at −135˚C until use. PBMCs were
thawed and centrifuged at 2000 rpm for 5 min. Viable cells were
counted using trypan blue exclusion test. PBMCs were seeded in
alpha-modified Minimum Essential Medium (aMEM; Invitrogen,
Carlsbad, CA, USA) supplemented with 20% heat inactivated FCS
(Lonza, Verviers, Belgium, selected batch), 2% pen-strep (Peni-
cillin 10,000 UI/ml, Streptomycin 10,000 UI/ml, Lonza, Verviers,
Belgium), and 2% l-glutamine (200 mM, Lonza, Verviers, Bel-
gium) and activated with anti-CD3 and anti-CD28 linked with
linker goat-anti-mouse antibody (BD Pharmingen, San Diego, CA,
USA). 5× 104 PBMCs in 100µl expansion medium were seeded
per well in round-bottom 96-well plates (Nunc, Roskilde, Den-
mark) and incubated for 5 days. The immunosuppressive capacity
of factors secreted by MSCs was evaluated by using the CM from
the MSC culture conditions described earlier. One hundred micro-
liters of CM of MSCs incubated with each of the SFs, except one of
the OA donors were no SF was left, was added in triplicate to the
PBMCs for 5 days. CM of MSCs without SF and unconditioned
medium, identical to the medium used in the CM except for the
fact that it had not been in contact with MSCs, were added in
triplicate as a control. To correct for direct effects of the SF present
in the CM on the PBMCs we added controls of medium not con-
ditioned by MSCs with similar concentration of SF of each of the
donors. At day four of incubation, 3H-thymidine (0.5µCi/well;
Perkin Elmer, Inc., San Jose, CA, USA) was added. At day five, after
16 h of incorporation of 3H-thymidine, PBMCs were harvested,
and 3H-thymidine incorporation measured using a β-plate reader
(Wallac 1450 MicroBeta TriLux Liquid Scintillation Counter and
Luminometer, Perkin Elmer, Inc., San Jose, CA, USA).
DATA ANALYSIS
Statistical difference in gene expression by MSCs conditioned
with SF(OA), SF(RA), and SF(control) was analyzed by using a
mixed linear model in which condition(SF of OA, RA, or no joint
pathology donors) was considered a fixed factor and the differ-
ent SF donors for all conditions a random factor. Values for the
genes IDO, TNFa, and TGFb were log-transformed to approach
a normal distribution. Statistical differences of inhibitory capac-
ity of the different CM was analyzed by using a mixed linear
model in which condition (CM by MSCs incubated with OA,
RA, or control SF) was considered a fixed factor, different donors
a random factor and Sidak was used as adjustment for multi-
ple comparisons. Inhibitory effects of CM with SF compared to
SF only were explored by statistical analyses with the Wilcoxon
signed ranks test. Data are presented as the mean± standard
deviation and 2.5–97.5 percentile. P-value of ≤0.05 was con-
sidered statistical significant; ∗P < 0.05, ∗∗P < 0.001. Analyses
were performed using SPSS 17.0 Statistics (SPSS, Inc., Chicago,
IL, USA).
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RESULTS
EFFECT OF SF ON GENE EXPRESSION OF MSCs
To evaluate the effect of SF on mRNA expression of IL-6, HGF,
IDO, TNFa, and TGFb1 by MSCs, MSCs were cultured in medium
containing 20% SF of each of the 15 different donors. Medium
with 1% ITS was used as SF free culture control and represented as
a dotted line in Figure 1. Addition of SF significantly up-regulated
IL-6 (2.43± 0.22-fold; P < 0.001) and IDO (1.72± 0.17-fold;
P = 0.007) expression. There is a trend of down-regulation of
TNFa albeit not significant. Gene expressions of HGF, TNFa, and
TGFb1 were not significantly affected by SF compared to the SF
free control (Figure 1).
Next, we explored the effect of three different types of SF
separately. MSCs cultured in SF(OA) expressed IDO 1.69-fold
(P = 0.048) higher than MSCs cultured in SF(control). For SF(RA)
we also found an up-regulation in gene expression for IDO, albeit
FIGURE 1 | Effect of different synovial fluids on gene expression of
immunomodulatory factors by MSCs. Gene expressions expressed in cycle
thresholds (ct) normalized to BKI in every sample. MSCs were cultured in
20% SF of six OA and six RA donors and three donors without joint
pathology. Dotted lines indicate the average gene expression in MSCs
cultured in medium without SF. The data are presented as median
scatterplots, each point represents an average of three measurements per
donor (Mean±SD). SF, synovial fluid; SF(control, OA, and RA) culture media
of the MSCs supplemented with respectively non-pathological SF, OA SF, and
RA SF. IDO, indoleamine 2,3-dioxygenase; IL-6, interleukin-6; TNFa, tumor
necrosis factor-alpha; TGFb1, transforming growth factor-beta 1; HGF,
hepatocyte growth factor; BKI, BestKeeper Index consisting of: GAPDH, UBC,
and HPRT. *Expression in MSCs after culture in SF(OA) different from
SF(control) by mixed linear test of these two conditions, P <0.05.
Frontiers in Immunology | Alloimmunity and Transplantation August 2012 | Volume 3 | Article 231 | 4
Leijs et al. The effect of synovial fluids on immunomodulation by MSCs
not significant which is probably caused by the large variation
between the six different RA donors. No further significant dif-
ferences in gene expression of IL-6, TNFa, TGFb1, and HGF were
found between MSCs cultured in the three different SFs (Figure 1).
IDO activity of MSCs was analyzed by an l-kynurenine assay on
all different CM with SF corrected for l-kynurenine content in SF
of that donor. No significant differences of IDO activity by MSCs
cultured in SF of different donors were found (data not shown).
EFFECT OF CONDITIONED MEDIUM ON LYMPHOCYTE PROLIFERATION
Conditioned medium harvested after culturing MSCs in 20% SF
was used to analyze the effect of secreted factors of MSCs on the
proliferation of CD3/CD28 activated PBMCs (Figure 2). The CM
was mixed 1:1 with fresh medium and added to PBMCs. CM of
MSCs without SF (CM control) did not influence PBMC prolifer-
ation. There was no difference in PBMC proliferation between CM
of MSCs without SF and CM of MSCs incubated in SF(control).
There was significantly more inhibition of PBMC proliferation by
CM with SF(OA) compared to CM with SF(control; P < 0.001)
and by CM with SF(RA) compared to CM with SF(control;
P < 0.001).
To correct for direct effects of SF on PBMCs we added controls
with unconditioned medium with SF. The SF appeared to inhibit
PBMC proliferation, independent of disease state. A preliminary
experiment with different concentrations of SF(OA) indicated that
the effect of SF on lymphocyte proliferation is dose dependent
(data not shown).
FIGURE 2 | Effect of conditioned medium of MSCs with different types
of synovial fluid (SF) on proliferation of CD3/28 activated PBMCs.
Box-and-Whisker plot 2.5–97.5 percentile; *P <0.05; **P <0.001; #P <0.05
between CM and SF effect. CM, conditioned medium; SF, synovial fluid;
(medium) culture medium with ITS; (CM control) MSC conditioned medium
consisting of only culture medium with ITS; (Medium control) Only culture
medium with ITS; SF (control) synovial fluid of donors without joint
pathology; SF(OA) synovial fluid of patients with osteoarthritis; SF(RA)
synovial fluid of patients with rheumatoid arthritis.
Conditioned medium of MSCs incubated in SF(control) caused
significantly less inhibition of PBMC proliferation than uncondi-
tioned medium [medium that was not in contact with MSCs but
contained SF(control)]. No significant differences in proliferation
inhibition were found between OA and RA CM (Figure 2).
DISCUSSION
The aim of the study was to evaluate to what extent SF influences
the immunomodulation of MSCs. This study indicates that SF
can influence the expression of genes in MSCs that are involved
in immunomodulation. Moreover, factors secreted by MSCs incu-
bated with SF(OA and RA) inhibited the proliferation of activated
lymphocytes significantly more than factors secreted by MSCs
incubated without SF or with SF(control). This indicates that fac-
tors in diseased SF stimulate MSCs to secrete anti-inflammatory
factors.
To our knowledge this is the first report on the effect of SF
on the expression and secretion of immunomodulatory factors
in MSCs. This information is important for the application of
MSCs in joints of patients with joint diseases. Upon injection
or implantation in the joint the MSCs will be exposed to SF. SF
is known to contain a mix of factors secreted by the tissues of
the joint. In the current study we investigated whether SF from
non-diseased and OA and RA donors triggers MSCs to have an
immunomodulatory effect. We demonstrated that SF(OA) can up-
regulate MSC gene expression of IDO. In addition, MSCs treated
with SF up-regulated expression of IL-6, a pleiotropic cytokine
with pro-inflammatory functions, but also involved in regenera-
tive processes and regulation of metabolism (Scheller et al., 2011).
Which factor(s) secreted by MSCs cause the immunomodulatory
effects cannot be concluded from our study and deserves further
investigation.
We hypothesized that MSCs will be triggered by a catabolic
environment in the joint to become immunomodulatory and
that SF(RA) will induce large anti-inflammatory and SF(OA) will
induce mild anti-inflammatory effects compared to SF(control).
Our data could partly confirm this hypothesis. Diseased SF trig-
gered MSCs to become immunomodulatory but we did not find
any differences between the effects of SF(OA and RA) on gene
expression of MSCs and PBMC proliferation. Whereas we assumed
SF(control) would be immunological quiescent and diseased SF
inflammatory, surprisingly we found inhibited lymphocyte pro-
liferation by all SFs. This inhibition further increased by secreted
factors of MSCs cultured with addition of SF(OA or RA), albeit
non-significant. Surprisingly in the presence of SF(control), the
inhibition of lymphocyte proliferation by SF was significantly
reduced. This unexpected outcome suggests different effects of
non-pathologic SF on excretion of factors by MSCs. Since the
composition of healthy or diseased SF is not precisely known,
it is difficult to explain the effects of SFs on MSCs and on
PBMCs.
To provide a relatively clean way to study the effect of factors
secreted by MSCs on lymphocyte proliferation, we used CM of
MSCs exposed to SF. Different durations of exposure to SF and
direct interactions between lymphocytes and MSCs in the pres-
ence of SF can play a role as well and this should be investigated
in the future.
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We here demonstrate that MSCs can be differently influenced
by exposure to SF from diseased and non-pathological joints,
but the effects were small compared to commonly used stimu-
lation with TNFa and IFNg (Crisostomo et al., 2008; Hemeda
et al., 2010; Hoogduijn et al., 2010). This might explain why
resident MSCs in joints cannot prevent disease development;
they might not be properly activated by the environment. It
can also be regarded as somewhat disappointing in respect to
the application of MSCs in the diseased joint since exposure to
SF might not be sufficient to stimulate the healing activity of
the MSCs.
Although it is unknown which factor in SF does stimulate
MSCs, we performed ELISA on SFs. SF(RA) has a higher con-
centration of IL-6 compared to SF(OA; 7380 vs. 525.4 pg/ml;
P = 0.009) and SF(control; 7380 vs. 22.4 pg/ml; P = 0.024), con-
firming previous reports (Kokebie et al., 2011). TNFa was mea-
surable in only one OA donor and two RA donors and IFNg
was measurable in only one OA and one RA SF donor (data
not shown). Neither of these cytokines correlated with the effects
of SF on MSCs or PBMCs but we can not exclude that other
factors evoke an effect on MSCs. Moreover, in vivo, direct con-
tact with MSCs and inflamed synovial tissue, immune cells in
the synovium, or degenerated cartilage might, however, activate
the MSCs. Finally, it should be noted that we have selected
a limited number of immunomodulatory factors to evaluate
the effect on MSCs and we cannot exclude that SF stimulates
other processes in MSCs that can effect healing of the diseased
joint.
Since the SFs were considered as redundant materials, ethi-
cal regulations preclude the availability of patient-specific infor-
mation. It is very likely that the OA and RA patients used
medication that might have influenced the compositions of the
SFs. It has been demonstrated that analgesic drugs, NSAIDs,
and DMARDs can change concentrations of immunomodula-
tory factors in SF (Bianchi et al., 2003, 2007; Alvarez-Soria
et al., 2006). Use of different types of medication within donor
groups could be a cause for the high variations within the
groups.
Moreover, this explorative study was performed with SF of six
OA donors, six RA donors, and three donors without joint pathol-
ogy. To gain sufficient power the study should be repeated with
larger numbers of pathological and non-pathological SFs. SF was
used in a concentration of 20% for 48 h in analyses on MSCs. It
remains unknown how MSCs will react on 100% SF over a longer
period of time, which eventually will be the environment for MSCs
when they are injected in a joint.
Although MSCs appear a promising therapy for degenerative
joint diseases, the working mechanisms are not entirely clear. In
animal studies it is possible to track MSCs injected in the joint.
It was demonstrated that some of the injected MSCs stayed in
the joint and adhered to the synovium or affected areas (Qi et al.,
2011; Sato et al., 2012) from where they could exert a modulating
effect and decrease the inflammatory or catabolic environment in
diseased joints. The immunomodulatory capacity of MSCs can be
useful for patients with OA and RA. Good therapeutic options for
RA are already available, such as DMARDs and biologicals. How-
ever MSCs are capable of secreting many different factors, possibly
for a prolonged time, which can influence many different mecha-
nisms and are not restricted to one single target, unlike for example
anti-TNFα. This explorative study shows that (1) SF can influence
the expression of genes by MSCs involved in immunomodulation
and (2) factors in CM by MSCs cultured with arthritic SF inhibit
lymphocyte proliferation more than factors in CM by MSCs cul-
tured without SF or with SF(control). These results warrant further
research to examine the potential application of MSC therapy in
arthritic joints.
ACKNOWLEDGMENTS
The authors are grateful to N. Kops, J. L. M. Koevoet, and F. K.
F. Mensah (Erasmus MC, University Medical Centre Rotterdam,
The Netherlands) for technical assistance; to A.M.C. Mus (Eras-
mus MC, University Medical Centre Rotterdam, The Netherlands)
for kindly providing synovial fluids of patients with rheuma-
toid arthritis. Furthermore, the authors gratefully acknowledge
the financial support of the NIRM (Netherlands Institute of
Regenerative Medicine).
REFERENCES
Alvarez-Soria, M. A., Largo, R., San-
tillana, J., Sanchez-Pernaute, O.,
Calvo, E., Hernandez, M., Egido, J.,
and Herrero-Beaumont, G. (2006).
Long term NSAID treatment
inhibits COX-2 synthesis in the
knee synovial membrane of patients
with osteoarthritis: differential
proinflammatory cytokine profile
between celecoxib and aceclofenac.
Ann. Rheum. Dis. 65, 998–1005.
Bianchi, M., Broggini, M., Balzarini,
P., Baratelli, E., Ferrario, P., Pan-
erai, A. E., and Sacerdote, P.
(2003). Effects of tramadol on
synovial fluid concentrations of
substance P and interleukin-6 in
patients with knee osteoarthritis:
comparison with paracetamol. Int.
Immunopharmacol. 3, 1901–1908.
Bianchi, M., Broggini, M., Balzarini,
P., Franchi, S., and Sacerdote, P.
(2007). Effects of nimesulide on pain
and on synovial fluid concentra-
tions of substance P, interleukin-
6 and interleukin-8 in patients
with knee osteoarthritis: compari-
son with celecoxib. Int. J. Clin. Pract.
61, 1270–1277.
Caplan, A. I. (1991). Mesenchymal stem
cells. J. Orthop. Res. 9, 641–650.
Caplan, A. I. (1994). The mesen-
genic process. Clin. Plast. Surg. 21,
429–435.
Caplan, A. I., and Dennis, J. E. (2006).
Mesenchymal stem cells as trophic
mediators. J. Cell. Biochem. 98,
1076–1084.
Chen, L., Tredget, E. E., Wu, P. Y.,
and Wu, Y. (2008). Paracrine fac-
tors of mesenchymal stem cells
recruit macrophages and endothe-
lial lineage cells and enhance
wound healing. PLoS ONE 3, e1886.
doi:10.1371/journal.pone.0001886
Chen, X., Armstrong, M. A., and Li, G.
(2006). Mesenchymal stem cells in
immunoregulation. Immunol. Cell
Biol. 84, 413–421.
Crisostomo, P. R., Wang, Y., Markel, T.
A., Wang, M., Lahm, T., and Mel-
drum, D. R. (2008). Human mes-
enchymal stem cells stimulated by
TNF-alpha, LPS, or hypoxia pro-
duce growth factors by an NF kappa
B- but not JNK-dependent mech-
anism. Am. J. Physiol. Cell Physiol.
294, C675–C682.
Deans, R. J., and Moseley, A. B. (2000).
Mesenchymal stem cells: biology and
potential clinical uses. Exp. Hematol.
28, 875–884.
Eggenhofer, E., Steinmann, J. F., Ren-
ner, P., Slowik, P., Piso, P., Geissler, E.
K., Schlitt, H. J., Dahlke, M. H., and
Popp, F. C. (2010). Mesenchymal
stem cells together with mycophe-
nolate mofetil inhibit antigen pre-
senting cell and T cell infiltration
into allogeneic heart grafts. Transpl.
Immunol. 24, 157–163.
Findlay,D. M.,and Haynes,D. R. (2005).
Mechanisms of bone loss in rheuma-
toid arthritis. Mod. Rheumatol. 15,
232–240.
Goldring, M. B. (2000). The
role of the chondrocyte in
osteoarthritis. Arthritis Rheum. 43,
1916–1926.
Goldring, M. B., and Marcu, K.
B. (2009). Cartilage homeostasis
in health and rheumatic diseases.
Arthritis Res. Ther. 11, 224.
Frontiers in Immunology | Alloimmunity and Transplantation August 2012 | Volume 3 | Article 231 | 6
Leijs et al. The effect of synovial fluids on immunomodulation by MSCs
Hemeda, H., Jakob, M., Ludwig, A.
K., Giebel, B., Lang, S., and Bran-
dau, S. (2010). Interferon-gamma
and tumor necrosis factor-alpha dif-
ferentially affect cytokine expression
and migration properties of mes-
enchymal stem cells. Stem Cells Dev.
19, 693–706.
Hoogduijn, M. J., Popp, F., Verbeek, R.,
Masoodi, M., Nicolaou, A., Baan,
C., and Dahlke, M. H. (2010).
The immunomodulatory properties
of mesenchymal stem cells and
their use for immunotherapy. Int.
Immunopharmacol. 10, 1496–1500.
Kim, D. H., Yoo, K. H., Choi, K. S., Choi,
J., Choi, S. Y., Yang, S. E., Yang, Y. S.,
Im, H. J., Kim, K. H., Jung, H. L.,
Sung, K. W., and Koo, H. H. (2005).
Gene expression profile of cytokine
and growth factor during differenti-
ation of bone marrow-derived mes-
enchymal stem cell. Cytokine 31,
119–126.
Klyushnenkova, E., Mosca, J. D., Zer-
netkina, V., Majumdar, M. K.,
Beggs, K. J., Simonetti, D. W.,
Deans, R. J., and Mcintosh, K. R.
(2005). T cell responses to allo-
geneic human mesenchymal stem
cells: immunogenicity, tolerance,
and suppression. J. Biomed. Sci. 12,
47–57.
Kokebie, R., Aggarwal, R., Lidder, S.,
Hakimiyan, A. A., Rueger, D. C.,
Block, J. A., and Chubinskaya,
S. (2011). The role of synovial
fluid markers of catabolism
and anabolism in osteoarthritis,
rheumatoid arthritis and asympto-
matic organ donors. Arthritis Res.
Ther. 13, R50.
Landgraf, K., Brunauer, R., Lep-
perdinger, G., and Grubeck-
Loebenstein, B. (2011). The
suppressive effect of mesenchymal
stromal cells on T cell proliferation
is conserved in old age. Transpl.
Immunol. 25, 167–172.
Lee, D. M., and Weinblatt, M. E. (2001).
Rheumatoid arthritis. Lancet 358,
903–911.
Meisel, R., Brockers, S., Heseler, K.,
Degistirici, O., Bulle, H., Woite, C.,
Stuhlsatz, S., Schwippert, W., Jager,
M., Sorg, R., Henschler, R., Seissler,
J., Dilloo, D., and Daubener, W.
(2011). Human but not murine mul-
tipotent mesenchymal stromal cells
exhibit broad-spectrum antimicro-
bial effector function mediated
by indoleamine 2,3-dioxygenase.
Leukemia 25, 648–654.
Minguell, J. J., Erices, A., and Con-
get, P. (2001). Mesenchymal stem
cells. Exp. Biol. Med. (Maywood) 226,
507–520.
Qi,Y., Feng, G., andYan,W. (2011). Mes-
enchymal stem cell-based treatment
for cartilage defects in osteoarthritis.
Mol. Biol. Rep. 39, 5683–5689.
Sato, M., Uchida, K., Nakajima, H.,
Miyazaki, T., Rodriguez Guerrero,
A., Watanabe, S., Roberts, S., and
Baba, H. (2012). Direct transplan-
tation of mesenchymal stem cells
into the knee joints of Hartley
strain guinea pig with spontaneous
osteoarthritis. Arthritis Res. Ther. 14,
R31.
Scheller, J., Chalaris, A., Schmidt-Arras,
D., and Rose-John, S. (2011). The
pro- and anti-inflammatory prop-
erties of the cytokine interleukin-
6. Biochim. Biophys. Acta 1813,
878–888.
Schinkothe, T., Bloch, W., and Schmidt,
A. (2008). In vitro secreting profile
of human mesenchymal stem cells.
Stem Cells Dev. 17, 199–206.
Scott, D. L., Wolfe, F., and Huizinga,
T. W. (2010). Rheumatoid arthritis.
Lancet 376, 1094–1108.
Siegel, G., Schafer, R., and Dazzi,
F. (2009). The immunosuppressive
properties of mesenchymal stem
cells. Transplantation 87, S45–S49.
Solchaga, L. A., Welter, J. F., Lennon, D.
P., and Caplan, A. I. (2004). Gener-
ation of pluripotent stem cells and
their differentiation to the chondro-
cytic phenotype. Methods Mol. Med.
100, 53–68.
Sze, S. K., De Kleijn, D. P., Lai, R. C., Khia
Way Tan, E., Zhao, H.,Yeo, K. S., Low,
T. Y., Lian, Q., Lee, C. N., Mitchell,
W., El Oakley, R. M., and Lim, S.
K. (2007). Elucidating the secretion
proteome of human embryonic stem
cell-derived mesenchymal stem cells.
Mol. Cell Proteomics 6, 1680–1689.
Weissmann, G. (2006). The pathogen-
esis of rheumatoid arthritis. Bull.
NYU Hosp. Jt. Dis. 64, 12–15.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 29 March 2012; paper pend-
ing published: 25 April 2012; accepted:
14 July 2012; published online: 02 August
2012.
Citation: Leijs MJC, van Buul GM, Lub-
berts E, Bos PK, Verhaar JAN, Hoog-
duijn MJ and van Osch GJVM (2012)
Effect of arthritic synovial fluids on the
expression of immunomodulatory factors
by mesenchymal stem cells: an explorative
in vitro study. Front. Immun. 3:231. doi:
10.3389/fimmu.2012.00231
This article was submitted to Frontiers
in Alloimmunity and Transplantation, a
specialty of Frontiers in Immunology.
Copyright © 2012 Leijs, van Buul, Lub-
berts, Bos, Verhaar, Hoogduijn and van
Osch. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the original
authors and source are credited and sub-
ject to any copyright notices concerning
any third-party graphics etc.
www.frontiersin.org August 2012 | Volume 3 | Article 231 | 7
